FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

Zinger Key Points

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s AZN Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

The approval was based on results from the TROPION-Breast01 Phase 3 trial.

Read Next: AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline

In TROPION-Breast01, Datroway significantly reduced the risk of disease progression or death by 37% compared to the investigator’s choice of chemotherapy as assessed by blinded independent central review (BICR). Median progression-free survival (PFS) was 6.9 months in patients treated with Datroway versus 4.9 months with chemotherapy.

The safety profile of Datroway was consistent with the known profile of this medicine, with no new safety concerns identified.

In the Datroway arm, the interstitial lung disease (ILD) rate was 4.2% and the majority of events were low grade.

Datroway is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo DSNKY DSKYF, and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Recently, the FDA approved AstraZeneca’s Calquence in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.

Price Action: AZN stock is up 2.43% at $68.22 at last check Tuesday.

Read Next:

Photo via Shutterstock.

AZN Logo
AZNAstraZeneca PLC
$69.640.13%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
43.81
Growth
97.36
Quality
46.76
Value
19.16
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech stocks could rise after FDA approval?
How will AstraZeneca benefit from Datroway?
Which pharmaceutical companies are developing similar drugs?
What impact will Datroway have on cancer treatment costs?
Could Daiichi Sankyo see gains from this collaboration?
How might this approval affect oncology-focused ETFs?
What is the market potential for HER2-negative therapies?
Which healthcare investors are focused on ADCs now?
How will investors react to AstraZeneca's latest performance?
What trends are emerging in breast cancer therapeutics?
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...